These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 111446)

  • 21. The comparative effect of T4 and T3 on the TSH response to TRH in young adult men.
    Sawin CT; Hershman JM; Chopra IJ
    J Clin Endocrinol Metab; 1977 Feb; 44(2):273-8. PubMed ID: 402379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low setting of feedback regulation of TSH secretion by thyroxine in pituitary dwarfism with TSH-releasing hormone deficiency.
    Sato T; Ishiguro K; Suzuki Y; Taketani T; Isumisawa A
    J Clin Endocrinol Metab; 1976 Feb; 42(2):385-90. PubMed ID: 816807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum concentrations of thyroxine, 3,5,3'-triiodothyronine, thyrotropin, and prolactin in dogs before and after thyrotropin-releasing hormone administration.
    Kaufman J; Olson PN; Reimers TJ; Allen TA; Soderberg SF; Nett TM; Wheeler SL; Wingfield WE
    Am J Vet Res; 1985 Feb; 46(2):486-92. PubMed ID: 3922262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
    Shimon I; Cohen O; Lubetsky A; Olchovsky D
    Thyroid; 2002 Sep; 12(9):823-7. PubMed ID: 12481949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normal thyrotrophin response to intravenous thyrotrophin releasing hormone administration: the best index of optimal L-thyroxine therapy in primary hypothyroidism.
    Kabadi UM
    Postgrad Med J; 1985 Aug; 61(718):685-8. PubMed ID: 3929241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential changes in the pituitary thyroid axis after chronic TRH administration: effects on euthyroid and thyroxine treated female rats.
    Iglesias R; Llobera M; Montoya E
    Acta Endocrinol (Copenh); 1985 Jun; 109(2):237-42. PubMed ID: 3925674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial target organ resistance to thyroid hormone.
    Bode HH; Danon M; Weintraub BD; Maloof F; Crawford JD
    J Clin Invest; 1973 Apr; 52(4):776-82. PubMed ID: 4632689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free thyroid hormones and a third-generation TSH assay in the detection of hyperthyroidism during long-term thyroxine treatment in thyroid carcinoma patients.
    Taimela E; Koskinen P; Nuutila P; Nikkanen V; Saraste M; Taimela S; Irjala K
    Scand J Clin Lab Invest; 1995 Apr; 55(2):181-6. PubMed ID: 7667611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma.
    Mueller-Gaertner HW; Schneider C
    Clin Endocrinol (Oxf); 1988 Apr; 28(4):345-51. PubMed ID: 3142712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of pituitary TSH secretion in the patient with a hyperfunctioning thyroid nodule.
    Ridgway EC; Weintraub BD; Cevallos JL; Rack MC; Maloof F
    J Clin Invest; 1973 Nov; 52(11):2783-92. PubMed ID: 4201265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid-stimulating hormone (tsh), triiodothyronine (t3) and thyroxine (t4) response to intravenous and oral stimulation with synthetic thyrotropin-releasing hormone (trh) in young healthy adults.
    Vogt P; Girard J; Staub JJ
    Klin Wochenschr; 1978 Jan; 56(1):31-5. PubMed ID: 415173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of the thyrotropin response to thyrotropin-releasing hormone and its association with severity of critical illness.
    Sumita S; Ujike Y; Namiki A; Watanabe H; Kawamata M; Watanabe A; Satoh O
    Crit Care Med; 1994 Oct; 22(10):1603-9. PubMed ID: 7924372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seasonal variation of serum thyrotropin concentration and thyrotropin response to thyrotropin-releasing hormone in patients with primary hypothyroidism on constant replacement dosage of thyroxine.
    Konno N; Morikawa K
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1118-24. PubMed ID: 6804476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine.
    Mechelany C; Schlumberger M; Challeton C; Comoy E; Parmentier C
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):123-8. PubMed ID: 1934526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid-stimulating hormone, prolactin, and growth hormone response to thyrotropin-releasing hormone in treated children with congenital hypothyroidism.
    Sack J; Shafrir Y; Urbach D; Amado O
    Pediatr Res; 1985 Oct; 19(10):1037-9. PubMed ID: 3932951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different effects of oral doses of triiodothyronine or thyroxine on the inhibition of thyrotrophin releasing hormone (TRH) mediated thyrotrophin (TSH) response in man.
    Wenzel KW; Meinhold H; Schleusener H
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):42-8. PubMed ID: 808065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of prolonged oral administration of TRH on plasma levels of thyrotrophin and prolactin in normal individuals and in patients with primary hypothyroidism.
    Frey HM; Haug E
    Acta Endocrinol (Copenh); 1977 Aug; 85(4):744-52. PubMed ID: 407759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tartrate thyrotropin-releasing hormone treatment on serum thyrotropin, free triiodothyronine, free thyroxine and prolactin levels in patients with spinocerebellar degeneration.
    Merola B; Colao A; Di Renzo G; Filla A; Campanella G; Lombardi G
    Horm Res; 1992; 38(3-4):160-3. PubMed ID: 1306848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
    Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
    J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.